Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study by Ratzon, Einav et al.
RESEARCH ARTICLE Open Access
Platinum (IV)-fatty acid conjugates
overcome inherently and acquired Cisplatin
resistant cancer cell lines: an in-vitro study
Einav Ratzon1, Yousef Najajreh2, Rami Salem2, Hazem Khamaisie1, Martin Ruthardt3 and Jamal Mahajna1,4*
Abstract
Background: Platinum-based drugs are used as cancer chemotherapeutics for the last 40 years. However, drug
resistance and nephrotoxicity are the major limitations of the use of platinum-based compounds in cancer therapy.
Platinum (IV) complexes are believed to act as platinum prodrugs and are able to overcome some of platinum (II)
limitations.
Methods: A number of previously sensitized platinum (IV) complexes were evaluated for their anti-cancer activity
by monitoring ability to affect proliferation, clonigenicity and apoptosis induction of Cisplatin sensitive and resistant
cancer cells. In addition, the uptake of Cisplatin and the platinum (IV) derivatives to Cisplatin sensitive and resistant
cancer cells was monitored.
Results: The bis-octanoatoplatinum (IV) complex (RJY13), a Cisplatin derivative with octanoate as axial ligand, exhibited
strong anti-proliferative effect on the Cisplatin resistant and sensitive ovarian cells, A2780cisR and A2780, respectively.
Moreover, RJY13 exhibited good activity in inhibiting clonigenicity of both cells. Anti-proliferative activity of RJY13 was
mediated by induction of apoptosis. Interestingly, a bis-lauratopaltinum (IV) complex (RJY6) was highly potent in
inhibiting clonigenicity of both Cisplatin sensitive and Cisplatin resistant cells, however, exhibited reduced activity in
assays that utilize cells growing in two dimensional (2D) conditions. The uptake of Cisplatin was reduced by 30 % in
A2780 in which the copper transporter-1 (Ctr1) was silenced. Moreover, uptake of RJY6 was marginally dependent on
Ctr1, while uptake of RJY13 was Ctr1-independent.
Conclusions: Our data demonstrated the potential of platinum (IV) prodrugs in overcoming acquired and inherited
drug resistance in cancer cell lines. Moreover, our data demonstrated that the uptake of Cisplatin is partially dependent
on Ctr1 transporter, while uptake of RJY6 is marginally dependent on Ctr1 and RJY13 is Ctr1-independent. In addition,
our data illustrated the therapeutic potential of platinum (IV) prodrugs in cancer therapy.
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Background
cis-Diamminedichloroplatinum (II) [cis-[PtCl2(NH3)2],
CDDP, Cisplatin] known for decades as Peyrone’s salt,
was first synthesized by M. Peyrone in 1845. Its cyto-
toxic activity was reported in 1964 by Rosenberg [1], and
its anti-cancer activity in 1979. Cisplatin is routinely
employed for the treatment of testicular and ovarian
cancers and is being increasingly used against cervical,
bladder, and head/neck tumors. The mechanism of action
of Cisplatin is based on the intrastrand cross-linking of
the cis-Pt(NH3)2 unit to cellular DNA at two neighboring
guanine bases [2] and the consequent induction of cellular
apoptosis. Nevertheless, its full clinical utility is limited
due to some adverse side effects.
Primary and acquired drug resistance is a major limita-
tion of the platinum compounds use as an anti-cancer
therapy [3, 4]. The molecular mechanisms that underline
this chemo resistance are largely unknown. Possible mech-
anisms include decreased platinum accumulation, elevated
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drug inactivation by metallothionine and glutathione, and
enhanced DNA repair activity [2, 5]. Moreover, acquired
and inherited resistance of cancer cells were reported to
be also mediated by altered molecular mechanisms and
activated signaling pathways, such as the protein kinase B/
mammalian target of rapamycin (Akt/mTOR) which is
also implicated in Cisplatin resistance in human ovarian
cancer cells [6].
In an attempt to overcome the above mentioned short-
ages, two platinum compounds were introduced to the
clinic; Carboplatin and Oxaliplatin [7, 8]. Carboplatin,
though much less potent than Cisplatin, have shown fewer
adverse effects. Nonetheless, the drug showed cross-
resistance with Cisplatin, while Oxaliplatin did not [9, 10].
Moreover, a third generation orally available lipophilic plat-
inum, Satraplatin, demonstrated promising antitumor activ-
ity in multiple settings with a better toxicity profile than
Cisplatin [11, 12]. However, it has recently been abandoned
in phase III clinical trials for the treatment of hormone-
refractory prostate cancer [13]. It is well-established that
platinum (II) adverse effects are caused mainly by its ability
to non-selectively bind to macromolecules, leading to re-
duced bioavailability and increased toxic side effects.
Platinum (IV) complexes, on the other hand, have enor-
mous potential as anticancer agents in terms of both high
activity and low toxicity. These potential advantages of Plat-
inum (IV) complexes, which expected to remain in higher
oxidation state in the bloodstream, are derived from their
lower reactivity towards macromolecules, which enables to
diminish the loss of active drug and lower the incidence of
unwanted side reactions that lead to toxic side effects. The
octahedral platinum (IV) geometry makes these com-
pounds far more kinetically inert towards ligand exchange
reactions and less prone to substitution reactions in the
physiological media, thus making such compounds of high
interest in avoiding the adverse toxic effects seen with plat-
inum (II). In addition, once entered the cell, platinum (IV)
is bio- converted to the corresponding platinum (II) species
by expelling the axial ligands (Fig. 1). Together, the above
mentioned observations laid down the bases for the rational
that Platinum (IV) compounds have the potential of acting
as prodrugs for their counter platinum (II) active forms
(Fig. 1) [14]. However, the first such chemotherapeutic
agent, namely satraplatin, failed to receive approval. More-
over, others also questioned the above prodrug rational and
pointed toward the ability of paltinum (IV) prodrug to be
reduced extracellularly [15, 16].
Recently, a series of complexes of the general formula cis,
cis, trans-[diamminedichloro-bis-carboxylatoplatinum(IV)],
where the carboxylate ranges between heptanoate, octano-
ate, decanoate ,laurate, myristate, palmitoate , stearate , and
oleateandelaidate, were prepared (Fig. 1), characterized, and
their anti-proliferative and anti-clonigenicity properties
against cancer cells were evaluated. Our results showed that
complexes encompassing saturated fatty acid derivatives
were generally more potent than the unsaturated ones.
Two promising platinum (IV) prodrugs, RJY6 and
RJY13 were selected for the evaluation of their anti-cancer
activity against several cancer cell lines including ovarian
and colon cancer cells. Here, we report that while RJY13
was highly potent in inhibiting proliferation and clonigeni-
city of both Cisplatin sensitive and Cisplatin resistant can-
cer cells, RJY6 was highly active in the clonigenicity assay
but exhibited reduced activity in assays that utilize cells
growing in 2D condition (plastic). Moreover, uptake of the
two platinum (IV) prodrugs was largely Ctr1-independent
which accounts, in part, for the enhanced activity against
Cisplatin resistant cancer cells.
Methods
Materials
Cisplatin, Carboplatin and Oxaliplatin were purchased from
Sigma. Stock solutions were 25–50 mM in phosphate-
buffered saline (PBS) and dilution were made with PBS to
reach the appropriate concentrations in the different assays.
RJYs were synthesized at the laboratory of Anticancer
Drugs Research Lab, Faculty of Pharmacy, Al-Quds
University, Jerusalem, Abu-Dies, Palestine and dissolve
in dimethyl sulfoxide (DMSO) (25-50 mM) and diluted
to obtain final DMSO solutions of 0.1–0.5 % in the dif-
ferent assays.
Synthesized Platinum (IV) prodrugs were subjected to
proton nuclear magnetic resonance (1H-NMR) and
195Pt-NMR spectroscopy using Varian Unity Inova
500 MHz spectrometer equipped with a 5-mm switch-
able and data were processed using the VNMR software.
Moreover, infrared spectra were obtained from a KBr
matrix (4000–400 cm-1) using a PerkinElmer Precisely,
Spectrum 100, fourier transform infrared spectroscopy
(FT-IR) spectrometer. Furthermore, to all synthesized
prodrugs an Electrospray ionization mass spectrometry
(ESIMS) was performed using a ThermoQuest Finnigan
LCQ-Duo in the positive ion mode (Najajreh et al., in
preparation).
Obtained data for the compound RJY6 (Cis, cis, trans-
[diamminedichloro-bis-lauratoplatinum(IV)]) were as fol-
low: yellowish solid product with yield of 35 %, 195Pt-NMR:
(DMSO-d6, δ ppm) = 1204.25 and FT-IR (KBr) (cm-1):
3403(N-H), 1560 (C =O), 540(Pt-O). Obtained data for the
compound RJY13 (Cis, cis, trans-[diamminedichloro-bis-
octanoatoplatinum (IV)]): were as follow: yellowish solid
product with of 28 %, 195Pt-NMR: (DMSO-d6, δ
ppm) = 1203.40 and FT-IR (KBr) (cm-1): 3125 (N-H),
1580 (C = O), 527 (Pt-O).
Cells and cancer cell lines
Colon cancer (HT29), prostate cancer (PC3), Cisplatin
sensitive ovarian cancer (2780), and Cisplatin resistant
Ratzon et al. BMC Cancer  (2016) 16:140 Page 2 of 11
ovarian cancer cell lines (A780cisR) were obtained from
ATCC (ATCC, USA). Cells were grown in Roswell Park
Memorial Institute (RPMI) 1640 (Sigma, Rehovot, Israel)
containing 2 mM L-glutamine, 10 % fetal bovine serum
(FBS) , 100 IU/ml penicillin, and 100 μg/ml streptomycin
(PenStrep). The human embryonic kidney cell line 293A
(HEK293A), human embryonic kidney cell line 293 T
(HEK293T) and human foreskin fibroblast cells (HFF)
were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) medium (Sigma, Rehovot, Israel) supplemented
with 10 % fetal calf serum (FCS), 2 mM L-glutamine,
1 mM sodium pyruvate, and 1 % PenStrep (Biological In-
dustries, Israel). All cell lines were grown at 37 °C in a hu-
midified atmosphere with 5 % CO2.
Cell proliferation assay
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium
-5-carboxanilide) (XTT) assay was used as previously de-
scribed [17] to evaluate the cytotoxicity of the different
Cisplatin derivatives. Briefly, cells (1.5 × 104) were plated in
RPMI 1640 medium using 96-well plates for 24 h, and then
treated for an additional 72 h with the different Cisplatin
derivatives. A total of 50 μl of XTT solution were added to
each well and incubated for 3 h at 37 °C. The optical
density was measured by a multi-well plate spectrophotom-
eter at 450 nanometers with a references’ wavelength of
630 nm. The concentrations inhibiting cell proliferation by
50 % (IC50s) of all tested derivatives were calculated. The
experiment was performed in triplicate, and standard devia-
tions were also calculated.
Apoptosis assay
To monitor apoptosis potential of Cisplatin derivatives
we followed cleavage of poly ADP ribose polymerase
(PARP) protein [18]. Briefly, cells (2 × 105 cells/ml) were
treated with Cisplatin derivatives for the indicated time.
Cells were collected, washed once with cold PBS, and
lysed in buffer [10 mMTris-HCl (pH 7.4), 100 mMNaCl,
Cisplatin
Bioreduction
R =
Cisplatin (IV)
prodrugs
RJY6
RJY13
A
B
Fig. 1 Chemical structure of Cisplatin (IV) prodrugs and cellular bio-reduction. a. Bio-reduction of Cisplatin (IV) prodrugs to give rise to the
biologically active Cisplatin moiety and the different fatty acid ligands (R). b. Chemical structure of the two Cisplatin (IV) prodrugs; RJY6 and RJY13
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1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM
Na4P2O7, 2 mM Na3VO4, 1 % Triton x-100, 10 %
Glycerol, 0.1 % sodium dodecyl sulfate (SDS), 0.5 % deoxy-
cholate, 1 mM phenylmethylsulfonyl fluoride (PMSF), for
30 min at 4 °C. Cell lysate supernatants (40 μg protein/
each) were resolved on 8 % SDS-polyacrylamide gel electro-
phoresis, transferred to nitrocellulose membranes, and
analyzed by immune-blotting with an anti-cleaved PARP
antibody (Cell signaling technology, USA ). Anti α-tubulin
antibody (Santa Cruz Co., CA, USA) was used as a loading
control.
PathScan cleaved PARP (Asp214) sandwich enzyme-linked
immunosorbent assay (ELISA)
Cell lysates prepared from treated ovarian cancer cells
(30 h) were used for quantitative measurement of cleaved
PARP according to manufacturer’s instructions (Cell signal-
ing technology, USA). In our experiments, 20 μg of total
lysate proteins from each sample were utilized.
Clonigenicity assay
Clonigenicity assay was performed as previously describe
[19]. Briefly, cells (1 × 104) in 1 ml RPMI 10 % FBS
medium were diluted in 1 ml of 0.6 % agar to give a final
agar concentration of 0.3 % agar. The cells-agar mixture
was poured over a hardened agar base in wells of 12-well
plates and allowed to solidify. Once the top layer solidi-
fied, 1 ml of medium containing different treatments was
placed on top to keep the agar moist. The cells were
grown at 37 °C in a 5 % CO2 humidified atmosphere until
colonies were visible (2 weeks). The plates were stained
for 4 h with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT), and the dye was
extracted with 1 ml solubilization buffer (20 % SDS,
50 % N,N-dimethyl-formamide, 25 mM HCL) for 24 h.
The optical density was measured at 570 nm wavelength
with a reference wavelength of 630 nm.
Inductively coupled plasma mass spectrometry (ICP-MS)
To monitor the uptake potential of Cisplatin and Cisplatin
(IV) prodrugs into A2780, A2780cisR, and A2780 Ctr1− cell
lines, experiment was carried out as previously described
[20]. Briefly, cells were plated at 5×105 cells/ml, and on the
following day compounds RJY6, RJY13 (10 microM), and
Cisplatin (50 microM) were added for 1 h. Cells were
collected, washed four times with cold PBS. The cells were
counted, digested, and the amount of platinum in the cells
was determined by ICP-MS. The amount of paltinum/cells
was calculated.
Silencing of Ctr1 in A2780 cells
A2780 cells were transfected with three different shRNA
Ctr1 constructs (Sigma-Aldrich, Rehovot, Israel) according
to manufacturer instructions. Briefly, Ctr1 shRNA plasmid
DNA, pcMV-dR8.2 dvpr and pcMV-VSVG were co-
transfected into HEK293T cells (1.5×105cells\ml) using
Fugene 6 (Roche Applied Science, Penzberg, Germany)
according to manufacturer instructions. The supernatant of
the infected cells was collected 48 h post transfection and
used to infect A2780 cells, after which Puromycin resistant
clones were selected. Levels of Ctr1 were determined in
parental and Puromycin resistant A2780 clones to calculate
percentage of silencing.
Statistical analysis
Statistical analysis was performed using Student’s t-test,
with significant values set at *P < 0.05 or **P < 0.005.
Results
Evaluation the anti-proliferative effects of Cisplatin (IV)
prodrugs on ovarian cancer cell lines
Previously, a number of Cisplatin (IV) prodrugs carrying
fatty acid ligands were synthesized (Najajreh et al., in prep-
aration). In this report, we evaluated the activity of Cisplatin
(IV)-Fatty acid conjugates against A2780 and A2780cisR,
ovarian cancer cells that are sensitive and resistant to
Cisplatin, respectively (Fig. 1). The anti-proliferative effect
of Cisplatin (IV) fatty acid conjugates, in comparison to
Cisplatin and Oxaliplatin, are summarized in Table 1.
Data presented in Table 1 illustrated that the two ovarian
cancer cell lines showed varying sensitivity to Cisplatin,
with IC50 of 1.3 and 19.2 microM against A2780 and
A2780cisR, respectively. Similarly, Cisplatin (IV) fatty acid
conjugates exhibited variable potency against the two ovar-
ian cancer cell lines tested (Table 1). The IC50 values of the
two active derivatives, RJY6 and RJY13, were 0.7 and 0.08
microM, respectively, against the sensitive ovarian cancer
cells and 3.3 and 0.57 microM, respectively, against the
A2780cisR resistant ovarian cancer cells. Thus, RJY13
exhibited increased potency, ranged from 16 to 33 fold
against A2780 and A2780cisR, respectively. However, RJY6
exhibited a moderate increase in potency of about 5-6 fold
against the two ovarian cancer cell lines. Similarly, the plat-
inum (IV) prodrugs also exhibited enhanced activity against
K562; chronic myelogenous leukemia (CML) cell lines
(Table 1) and the two active platinum (IV) prodrugs, RJY6
and RJY13 exhibited enhanced anti-CML by 4 and 7 folds,
respectively, compared to Cisplatin.
Clonigenicity inhibition by Cisplatin (IV) prodrugs
Anchorage-independent growth of cells (three dimensional,
3D growth) is a typical characteristic of the tumorigenicity
of cancer cells in vitro [21]. Thus, the anti-clonigenicity
potential of the Cisplatin (IV) prodrugs was evaluated
(Fig. 2). Figure 2 shows a photograph of a representative
experiment conducted with A2780, A2780cisR, and HT29
cell lines. Clonigenicity inhibition was observed in Cisplatin
treated samples with IC50 of 2300 and 4200 nM when
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A2780 and A2780cisR, respectively, were used. Further-
more, Oxaliplatin exhibited enhanced potency toward the
two cell lines compared to Cisplatin, with IC50 of 180 and
1600 nM against A2780 and A2780cisR, respectively. Inter-
estingly, our platinum (IV) prodrugs exhibited enhanced
activity against both cell lines. Our data showed that RJY1,
RJY3, RJY4, RJY6, RJY13, RJY18 and RJY19 exhibited good
potency against A2780 cells with IC50 of 180, 70, 25, 15,
10, 150, and 120 nM, respectively, an increased potency
by 10–200 fold among the different derivatives and in
comparison to Cisplatin (Fig. 2e). Moreover, a number of
derivatives were also effective against the Cisplatin resist-
ant, A2780cisR, cell line, with comparable activity to that
observed against the sensitive cell lines, A2780. Of special
interest is the derivatives RJY1, RJY2, RJY6, RJY13, RJY18,
and RJY19 that effectively inhibited clonigenicity of the
Cisplatin resistant ovarian cell line with IC50 of 320, 210,
13, 10, 150, and 220 nM, respectively. The two derivatives,
RJY13 and RJY6, were significantly more potent than
Cisplatin or Oxaliplatin in inhibiting the clonigenicity of
the ovarian cancer cell lines tested (Fig. 2) with IC50s values
lower by more than 20–30 folds than Cisplatin. Moreover,
the Cisplatin (IV) prodrugs, and especially RJY13 and
RJY6, exhibited significant activity against the inherently
resistant cells such as HT29 and PC3 cell lines (Fig. 2).
Next, we selected RJY6 and RJY13 to evaluate their
ability to affect proliferation of non-cancerous cells using
the HFF, HEK293A and HEK293T cells. HEK293A is an
engineered HEK293 cells carrying human species C adeno-
virus serotype 5 (Ad5) DNA, while HEK293T is carrying
the simian vacuolating virus 40 (SV40) large T-antigen.
Cisplatin and other platinum (II) compounds exhibited a
moderate degree of selectivity toward cancer cells com-
pared to normal cells, mainly due to altered DNA repair
mechanism and status of p53 gene. In agreement with
published data, we observed that Cisplatin exhibited some
degree of selectivity toward A2780 ovarian cancer cell lines
compared to HFF, HEK293A and HEK293T (Table 2).
Similarly, carboplatin exhibited some degree of selectivity
toward the ovarian cancer cells compared to HEK293 cells.
Our two platinum (IV) prodrugs also exhibited selectivity
toward ovarian cancer cells. RJY13 was more potent against
A2780 compared to HEK293A/T by about 10 fold. Interest-
ingly, RJY6 exhibited better selectivity profile of 16 and 24
fold when comparing potency against A2780 to HEK293T
and HEK293A, respectively. Moreover, Cisplatin also exhib-
ited good selectivity when comparing potency between
A2780 to HFF cells. However, selectivity of RJY13 and RJY6
was reduced by 30 fold and enhanced by 117 fold, respect-
ively, arguing that RJY6 compound is expected to exhibit
reduced toxicity to normal tissues and will exhibit an im-
proved therapeutic window. Interestingly, Cisplatin, Carbo-
platin and RJY6, but not RJY13 exhibited potent activity
against HEK293T compared to HEK293A; probably due to
compromise DNA repair in HEK293T resulted from im-
paired function of p53 in those cells.
Induction of apoptosis by Cisplatin (IV) prodrugs in
cancer cell lines
To investigate whether the effect of the RJY prodrugs is
due to apoptosis induction or cell growth suppression, we
monitored the ability of the Cisplatin (IV) prodrugs to pro-
mote PARP cleavage as a marker of apoptosis induction
[18]. Ovarian cancer cells, A2780 and A2780cisR, were
treated for 30 h (Fig. 3) with different concentrations of
Cisplatin (IV) fatty acid conjugates and results were com-
pared to the effect obtained with Cisplatin. Results shown
in Fig. 3 illustrated that treatment with Cisplatin caused
very minimal cleavage of PARP in A2780cisR at concentra-
tions below 100 microM (Fig. 3b), while significant PARP
cleavage was observed in A2780 cells exposed to 25
microM (Fig. 3a). Interestingly, 5 microM of RJY13 was
sufficient to cause a significant PARP cleavage in A2780cisR
and A2780 cells (Fig. 3a and b), arguing that RJY13 exhib-
ited enhanced potency against the resistant as well as the
sensitive ovarian cancer cells. In contrast, exposer to RJY6
caused PARP cleavage in both A2780cisR and A2780 cells
using concentrations above 25 microM, demonstrating
enhanced potency to the resistant ovarian cancer cell line
in comparison to Cisplatin (Fig. 3a and b). Focusing on
Cisplatin resistant ovarian cancer cells (A2780cisR), we
Table 1 Anti-proliferative activity of Cisplatin (IV) prodrugs.
Anti-proliferative activity was determined according to Materials
and Methods. IC50s values of the different derivatives are in
microM. Data shown are of representative experiment with CV
below 15 % in all samples. Experiment was repeated three
times with comparable outcome
IC50 (μM)
Compound A2780 A2780cisR K562
Cisplatin 1.3 19.2 5.2
Oxaliplatin 12.7 15.5 3.2
Carboplatin 16.8 109 ND
RJY1 >20 >20 34
RJY2 15.3 6 3.8
RJY3 >20 15 9.4
RJY4 20 7 3.9
RJY5 >20 >20 >20
RJY6 0.7 3.3 1.3
RJY9 >20 >20 >20
RJY10 19.2 >20 >20
RJY11 >20 >20 >20
RJY13 0.08 0.57 0.7
RJY18 14 2.1 0.85
RJY19 12.7 10 9.3
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IC50 (nM)
HT29PC3A2780cisRA2780Compound
250070542002300Cisplatin
16005601600180Oxaliplatin
2500870320180RJY1
800100210230RJY2
2000500130070RJY3
230020020025RJY4
>50001000>5000800RJY5
20151315RJY6
>50001000>50004800RJY9
330060038001000RJY10
>50001000>50002650RJY11
60601010RJY13
230150150150RJY18
600520220120RJY19
A2780 A2780cisR HT29
Cisplatin
Oxaliplatin
RJY6
RJY9
RJY13
RJY11
5             0.5
Cisplatin
Oxaliplatin
RJY6
RJY9
RJY13
RJY11
Cisplatin
Oxaliplatin
RJY6
RJY9
RJY13
RJY11
A2780 A2780cisR HT29
A
B C D
E
0. 05    M5             0.5 0. 05    M5             0.5 0. 05    M
Fig. 2 Clonigenicity inhibition of Cisplatin (IV) prodrugs. Cancer cells A2780 (a, b), A2780cisR (a, c) and HT29 (a, d) were grown on soft agar and
treated with 5, 0.5 and 0.05 microM of Cisplatin, Oxaliplatin, RJY6, RJY9, RJY11 and RJY13 or solvent-treated cells (a) according to Materials and
Methods. e IC50s values of clonigenicity inhibition of the different derivatives are in nM. Data shown are of representative experiment with
coefficient of variation (CV) below 15 % in all samples. Experiment was repeated three times with comparable outcome
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performed quantitative measurement of cleaved PARP
using Pathscan cleaved PARP (Asp214) sandwich ELISA
assay (Cell signaling, USA). Results shown in Fig. 3c
demonstrated that Cisplatin was not active in inducing
PARP cleavage in A2780cisR cells and only at the highest
concentrations used, 25 microM, a 2.4 fold increase in the
amount of cleaved PARP was observed (Fig. 3c). In con-
trast, a significant level of cleaved PARP was observed when
A2780cisR were exposed to RJY13. Levels of cleaved PARP
were increased by 4, 34 and 37 fold when cells were
exposed to 1, 5 and 25 microM of RJY13, respectively
(Fig. 3c) compared to untreated sample. Moreover, levels of
cleaved PARP were also increased in cells treated with
RJY6, but to a lesser extent compared to RJY13 (Fig. 3c).
Levels of cleaved PARP were increased by 2, 3 and 21 fold
when cells were exposed to 1, 5 and 25 microM of RJY6,
respectively (Fig. 3c).
Involvement of Ctr1 in the uptake of Cisplatin and
platinum (IV) prodrugs
Enhanced expression of hCtr1 was associated with in-
creased accumulation of Cisplatin, arguing for a role of
Ctr1 in mediating Cisplatin uptake [22]. Thus, we moni-
tored the expression level of Ctr1 in A2780 and A2780cisR
cells. Data presented in Fig. 4a illustrated that Ctr1 is
expressed at very low levels in A2780cisR cells in compari-
son to the Cisplatin sensitive A2780 cell line. This argues
that reduced Ctr1 expression might contribute to the re-
duced sensitivity to Cisplatin observed in A2780cisR cells.
To further evaluate the role of Ctr1 in Cisplatin resistance,
we infected A2780 cells with three shRNA targeting the
human Ctr1 gene. Data presented in Fig. 4b demonstrated
that the expression of Ctr1 in the resulted clones, #352,
Table 2 Selectivity Index of Cisplatin and active Cisplatin (IV)
prodrugs. The IC50s of Cisplatin, RJY6 and RJY13 were determined
using A2780, HFF, HEK293A and HEK293T cells. Data shown are of
representative of three experiments with CV below 20 % in all
samples
IC50 (μM)
Compound A2780 HFF HEK293T HEK293A
Cisplatin 1.3 84 3.2 16.3
Carboplatin 16.8 ND 45 105
RJY6 0.7 82 11.8 17.3
RJY13 0.08 2.4 0.5 0.7
0  1 5 25  100   1   5  25 1  5   25 ( M)
0  1 5  25  1 5   1 5  25  ( M)
A2780
A2780CisR
Cisplatin RJY13 RJY6
Tubulin
c-PARP1
Cisplatin   RJY13 RJY6
Tubulin
c-PARP1
0 1 5 25 0 1 5 25 0 1 5 25
Cisplatin                RJY13                           RJY6
R
el
at
iv
e 
U
n
it
s
*
**
**
**
( M)
A
B
C
Fig. 3 PARP cleavage induced by Cisplatin (IV) prodrugs. A2780cisR (a, c) and A2780 (b) cells were treated with Cisplatin, RJY6 and RJY13 for 30 h as
described in Materials and Methods. Quantitative evaluation of cleaved PARP in A2780cisR cells exposed to Cisplatin, RJY6 and RJY13 at (1, 5 and 25
microM) (c) were performed as described in Materials and Methods. P values; * P < 0.05 and **P < 0.005
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#349, and #348, were silenced by 60, 5 and 90 %, respect-
ively (Fig. 4b). Next, we evaluated the consequence of
reduced expression of Ctr1 on Cisplatin uptake using ICP-
MS. Figure 4c showed that uptake of Cisplatin into A2780
was significantly higher in comparison to A2780cisR. More-
over, silencing of Ctr1 in clone #348 caused a significant
reduction (30 %) in Cisplatin uptake, but still higher than
that of A2780cisR, arguing for the possibility that other
transporters, alongside Ctr1, contribute to Cisplatin uptake
in A2780 cell lines [23]. Next, we evaluated the uptake of
RJY6 and RJY13 into the different A2780 cells. Figure 4d
showed that uptake of RJY13 and RJY6 was efficient in all
tested cells. Moreover, uptake of RJY13 and RJY6 was
significantly higher than that of Cisplatin. For example,
A2780 cells accumulated 0.00014 platinum /cells when they
were exposed to 50 microM Cisplatin for 1 h. The same
cells accumulated 0.0054 and 0.0041 platinum/cells when
RJY6 and RJY13 were used, respectively, an increase of 30
fold in the uptake of the derivatives, which might explain,
in part, the enhanced potency of RJY6 and RJY13 compared
to the parental drug, Cisplatin. Furthermore, uptake of
RJY11, a relatively non-active platinum (IV) derivative, was
close to background in all A2780 cells, arguing that the
activity of the different derivatives correlates with their cel-
lular uptake (data not shown). Interestingly, uptake of RJY6
was significantly lower in A2780 cells with silenced Ctr1
(clone #348), and that in contrast to uptake of RJY13 that
was not dependent on the presence of Ctr1 protein
(Fig. 4d).
Discussion
Previously, we evaluated the activity of a number of plat-
inum (IV) prodrugs for their anti-proliferative and cloni-
genicity inhibition of the CML cell lines (Najajreh et al., in-
preparation). In this study we focused on different parame-
ters of our platinum (IV) series and evaluated anti-cancer
activity targeting the A2780 and A2780cisR, Cisplatin sensi-
tive and resistant ovarian cancer cell lines, respectively,
including anti-proliferative, clonigenicity inhibition, apop-
tosis induction and drug uptake. In addition, we moni-
tored the ability of our novel compounds to exert anti-
proliferative and clonigenicity inhibition against inherently
Cisplatin resistant cell lines such as HT29 and PC3 cells.
In agreement with our previous data, two platinum (IV)
prodrugs, RJY6 and RJY13, exhibited potent activity
against ovarian cancer cells with comparable potency. In
contrast to Cisplatin, our novel Cisplatin derivatives exhib-
ited comparable activity against Cisplatin sensitive
(A2780) and resistant (A2780cisR) ovarian cancer cells.
However, we noticed a difference in the behavior of the
two Cisplatin derivatives. While RJY13 exhibited strong
anti-tumor activity in all in vitro assays, RJY6 was less po-
tent in experiments that were performed in 2D conditions
(anti-proliferation and apoptosis inducing assays) and
exhibited strong activity in clonigenicity inhibition. Inter-
estingly, we also observed significant differences in the se-
lectivity profile between RJY6 and RJY13 against the non-
cancerous cells, such as the HFF and HEK293A/T cells. In
general, RJY 6 was more selective compared to RJY13. For
example, by calculating the ratio of IC50s exhibited against
none cancerous cells (HFF) to the cancerous cell line
(A2780), we observed a ratio of 63, 30 and 117.2 when
Cisplatin, RJY13, and RJY6, respectively were used.
Moreover, comparable outcome were obtained when we
compared the relative toxicity to HEK293A in relation to
A2780 cells. This argues for an expected better toxicity
profile of RJY6, while an enhanced toxicity of RJY13, in
comparison to Cisplatin, when using in vivo systems. The
mechanisms underlining the differences in behavior of the
two compounds are not known and examining the in vivo
toxicity is required to evaluate the full potential of our
platinum (IV) prodrugs. In addition, mechanisms respon-
sible for the reduced activity of RJY6 in 2D conditions in
comparison to assays performed in 3D condition are yet
to be determined. However, we hypothesized that differ-
ences might relate to varying exposure time in the two
types of experiments. While 3D experiments required
longer exposure time compared to 2D assays (2 weeks
compared to 1–3 days) and therefore the difference in
activity might be due to in-efficient bio-conversion of
RJY6 compared to RJY13, a hypothesis awaiting experi-
mental validation.
To shed a light on the mechanism responsible for in-
creased potency of RJY6 and RJY13 in comparison to
Cisplatin, we evaluated the role of copper transporter, Ctr1,
in the uptake of Cisplatin in comparison to the two active
Cisplatin (IV) prodrugs. Initially, we noticed that the
Cisplatin resistant cells (A2780cisR) expressed very minimal
amount of Ctr1 protein in comparison to sensitive cell lines
(A2780), arguing for a potential role of Ctr1 in the acquired
Cisplatin resistance observed in A2780cisR cells (Fig. 4).
Next, we utilized shRNA approach to silence the Ctr1 gene
in the sensitive A2780 cell line. We observed that uptake of
Cisplatin was high in A2780 Ctr1+ cells, reduced by 70 % in
resistant A2780cisR and by 30 % in A2780 Ctr1− (clone
#348) cells (Fig. 4c), arguing that Ctr1 protein is partially
required for efficient Cisplatin uptake and other trans-
porters besides Ctr1 required for efficient influx of palti-
num compounds such as Ctr2 [24] and Organic Cation
Transporters (Oct 1, 2, 3 and Oct 6) [25, 26]. Interestingly,
uptake of RJY6 was marginally reduced upon Ctr1 silencing
by 25 %; arguing that uptake of RJY6 might be partially
dependent on the Ctr1 transporter. In contrast, uptake of
RJY13 was not affected by the reduced Ctr1 expression. In
fact, uptake of RJY13 was slightly higher in Ctr1 silenced
cells. Our current data are in agreement with previous data
reported by Ishida et al., 2002 and Pabla et al., 2009 demon-
strating that knockdown of Ctr1 reduced Cisplatin uptake
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into yeast and mammalian cells and blocked Cisplatin-in-
duced cell death [23, 27]. Moreover, Holzer et al. 2004
reported that Ctr1 controls the cellular accumulation of
Cisplatin, Carboplatin, and Oxaliplatin at low concen-
trations, however, accumulation of Oxaliplatin is not
dependent on Ctr1 at higher concentrations [22]. Our
working hypothesis argues that uptake of RJY6 and
RJY13 are largely Ctr1-independent and probably more
efficient than that of Cisplatin and hence the enhanced
activity. Moreover, similarly to other reported platinum
(IV) prodrugs, enhanced activity and ability to overcome
chemo resistance might be related to the lipophilicity of
the prodrugs that favors its cellular accumulation by
passive diffusion [28]. We expected that our platinum (IV)
prodrugs will exhibit similar cellular activity as platinum
(II). However, this assumption needed to be experimen-
tally validated. In some cases, Cisplatin prodrugs such as
Oxoplatin exhibit different intracellular effects mediated
by differences in induction of stress responses [29]. Never-
theless, our data illustrated the therapeutic potential of
platinum (IV) prodrugs in overcoming Cisplatin chemo
resistance in cancer cells and potential better in vivo cyto-
toxic profile for some of them.
Conclusion
In this report we explored the therapeutic potential of our
platinum (IV) prodrugs in inducing anti-cancer activity to
Cisplatin resistant and sensitive ovarian cancer cell lines
and showed that the uptake of Cisplatin is partially
dependent on Ctr1 transporter, while uptake of our plat-
inum (IV) prodrugs is largely Ctr1-independent. Moreover,
our results demonstrated the potential of platinum (IV)
prodrugs in overcoming acquired and inherited drug resist-
ance in cancer cell lines and their therapeutic potential in
cancer therapy.
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